MedTrace Logo

Resveratrol In Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)

NCT02245932 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-05-17

No results posted yet for this study

Summary

The primary objective is to investigate the efficacy of resveratrol on mitochondrial function in patients with COPD. The secondary objective is to investigate the effect of resveratrol on body composition, inflammatory status and mechanistic markers in blood, adipose and muscle tissue as well as a comprehensive assessment of metabolicand physical performance profile known to be affected by resveratrol.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DIETARY_SUPPLEMENT

Resveratrol

4 weeks of 150 mg resveratrol (2 times 75mg/day)

DIETARY_SUPPLEMENT

Placebo

4 weeks of placebo supplementation (two doses per day)

Sponsors & Collaborators

  • The Netherlands Asthma Foundation

    collaborator OTHER

  • DSM Nutritional Products, Inc.

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Annemie Schols, Prof. · Maastricht University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02245932 on ClinicalTrials.gov